Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats

Acta Pharmacologica Sinica

Volumn 27, Issue 9, 2006, Pages 1127-1136

  Liang, Yan Qi ^a   Tang, Xi Can ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

5 hydroxy tryptamine; Acetylcholine; Alzheimer's disease; Donepezil; Dopamine; Huperzine A; Norepinephrine; Rats; Rivastigmine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; HUPERZINE A; NEUROTRANSMITTER; NORADRENALIN; RIVASTIGMINE; SEROTONIN;

ACETYLCHOLINE BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ELECTROCHEMICAL DETECTION; ENZYME INHIBITION; FASCICULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; RAT; SEROTONIN BRAIN LEVEL;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; INDANS; MALE; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; PHENYLCARBAMATES; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SESQUITERPENES;

EID: 33748795335     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00411.x     Document Type: Article

References (39)

1. Alhainen K, Helkala EL, Reinikainen K, Riekkinen P Sr. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm 1993; 5: 185-92.
2. Barili P, De Carolis G, Zaccheo D, Amenta F. Sensitivity to ageing of the limbic dopaminergic system: a review. Mech Ageing Dev 1998; 106: 57-92.
3. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, et al. Kinetic and structural studies on the interaction of cholinesterase with the anti-Alzheimer drug rivastigmine. Biochemistry 2002; 41: 3555-64.
4. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
5. Brozoski T, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205: 929-32.
6. Costa LG, Schwab BW, Murphy SD. Tolerance to anticholinesterase compounds in mammals. Toxicology 1982; 25: 79-97.
7. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90.
8. Cuadra G, Summers K, Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacal Exp Ther 1994; 270: 277-84.
9. Davidson M, Bierer LM, Kaminsky R, Ryan TM, Davis KL. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Disease Assoc Disorders 1989; 3: 224-7.
10. Day J, Fibiger HC. Dopaminergic regulation of cortical acetylcholine release. Synapse 1992; 12: 281-6.
11. Decker MW, McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991; 7: 151-68.
12. Ellman GL, Courtney KD, Andre V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
13. Floresco SB, Seamans JK, Phillips AG. Selective roles for hippocampal, refrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J Neurosci 1997; 17: 1880-90.
14. Giacobini E, Becker R. Development of drugs for Alzheimer therapy: a decade of progress. In: Giacobini E, Becker R, editors. Alzheimer Disease: Therapeutic Strategies. Boston, MA: Birkhäuser Press; 1994. p 1-7.
15. Giacobini E, Cuadra G. Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini E, Becker R, editors. Alzheimer Disease: Therapeutic Strategies. Boston, MA: Birkhäuser Press; 1994. p 155-71.
16. Giacobini E, Zhu XD, Williams E, Sherman KA. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996; 35: 205-11.
17. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28: 199-206.
18. Haroutunian V, Santucci AC, Davis KL. Implications of multiple transmi tter system lesions for chol inominet ic therapy in Alzheimer's disease. Prog Brain Res 1990; 84: 333-46.
19. Hersi AI, Rowe W, Gaudreau P, Quirion R. Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats. Neuroscience 1995; 69: 1067-74.
20. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000; 20: 1-12.
21. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999; 380: 101-7.
22. Laganiere S, Corey J, Tang XC, Wulfert E, Hanin I. Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology 1991; 30: 763-9.
23. Levy A, Kong RM, Stillman MJ, Shukitt-Hale B, Kadar T, Rauch TM, et al. Nimodipine improves spatial working memory and elevates hippocampal acetylcholine in young rats. Pharmacol Biochem Behav 1991; 39: 781-6.
24. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Rev 2004; 45: 38-78.
25. McCarthy G, Blamire AM, Puce A. Functional magnetic resonance imaging of human prefrontal cortex activation during a spatial working memory task. Proc Natl Acad Sci USA 1994; 91: 8690-4.
26. Pang YP, Kozikowski AP. Prediction of the binding site of huperzine A in acetylcholinesterase by docking studies. J Comput Aided Mol Des 1994; 8: 669-81.
27. Paxinos G, Watson C, editors. The rat brain in stereotaxic coordinates. Sydney: Academic Press; 1997.
28. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid (-)-huperzine A. Natural Struct Biol 1997; 4: 57-63.
29. Scali C, Casamenti F, Pazzagli M, Bartolini L, Pepeu G. Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci Lett 1994; 170: 117-20.
30. Steckler T, Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 1995; 67: 165-99.
31. Sugimoto H, Ogura H, Arai Y, Limura Y, Yamanishi Y. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 2002; 89: 7-20.
32. Taghzouti K, Le Moal M, Simon H. Dopaminergic innervation of the lateral septum and learning processes. Neurosci Lett Suppl 1986; 26: s332.
33. Tang XC. Huperzine A (Shuangyiping): A promising drug for Alzheimer's disease. Acta Pharmacol Sin 1996; 17: 481-4.
34. Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276-85.
35. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill; 1996. p 161-76.
36. Trabace L, Coluccia A, Gaetani S, Tattoli M, Cagiano R, Pietra C, et al. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res 2000; 865: 268-71.
37. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1-26.
38. Weinstock M, Razin M, Chorev M, Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm 1994; 43: 219-25.
39. Zhu XD, Giacobini E. Second generation cholinesterase inhibitors: effect of (L)-huperzine A on cortical biogenic amines. J Neurosci Res 1995; 41: 828-35.